Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
COLLEGIUM PHARMACEUTICAL, INC (COLL)
|
Add to portfolio |
|
|
|
| Price: |
$19.09
| | Metrics |
| OS: |
34.6
|
M
| |
-1
|
% ROE
|
| Market cap: |
$660
|
M
| |
24
|
% ROIC
|
|
Net cash:
|
$63.9
|
M
| |
$1.85
|
per share
|
|
EV:
|
$596
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
$92.5
|
M
| |
6.4
|
x EV/EBIT
|
| EPS |
($0.41)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 463.9 | 276.9 | 310.0 | 296.7 | 280.4 | 28.5 | 1.7 | 0.0 |
| Revenue growth | 67.6% | -10.7% | 4.5% | 5.8% | 884.7% | 1564.3% | | |
| Cost of goods sold | 254.4 | 126.3 | 130.2 | 208.4 | 275.5 | 2.6 | 0.2 | 0.0 |
| Gross profit | 209.5 | 150.6 | 179.8 | 88.3 | 4.9 | 25.9 | 1.5 | 0.0 |
| Gross margin | 45.2% | 54.4% | 58.0% | 29.8% | 1.7% | 90.9% | 87.6% | |
| Selling, general and administrative | 172.2 | 119.0 | 113.8 | 116.4 | 126.8 | 92.8 | 80.6 | 18.9 |
| Research and development | 4.0 | 9.5 | 9.8 | 10.3 | 8.7 | 8.6 | 14.9 | 8.0 |
| EBITA | 33.3 | 22.2 | 56.2 | -9.0 | 89.1 | -75.4 | -93.7 | -26.9 |
| EBITA margin | 7.2% | 8.0% | 18.1% | -3.0% | 31.8% | -264.9% | -5475.5% | |
| Amortization of intangibles | | | | 14.8 | 109.8 | | 0.4 | |
| EBIT | 33.3 | 22.2 | 56.2 | -23.7 | -20.7 | -75.4 | -94.1 | -26.9 |
| EBIT margin | 7.2% | 8.0% | 18.1% | -8.0% | -7.4% | -264.9% | -5498.7% | |
| Pre-tax income | -28.8 | -3.4 | 27.6 | -22.7 | -39.1 | -74.9 | -94.2 | -27.3 |
| Income taxes | -3.8 | -74.9 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 13.3% | 2219.7% | 3.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -25.0 | 71.5 | 26.8 | -22.7 | -39.1 | -74.9 | -94.2 | -27.3 |
| Net margin | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% | |
| |
| Diluted EPS | ($0.74) | $1.74 | $0.76 | ($0.68) | ($1.19) | ($2.47) | ($3.88) | ($2.01) |
| Shares outstanding (diluted) | 33.8 | 41.0 | 35.2 | 33.5 | 33.0 | 30.3 | 24.3 | 13.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|